41P - The in vitro and in vivo effects of mesenchymal stem cells on breast cancer cells
| Date | 04 May 2017 |
| Event | IMPAKT 2017 |
| Session | Welcome reception and Poster Walk |
| Topics | Breast Cancer Pathology/Molecular Biology Basic Scientific Principles |
| Presenter | Tetiana Herheliuk |
| Authors |
T. Herheliuk1, O. Perepelytsina1, O. Yakymchuk1, L. Ostapchenko2, M. Sydorenko1
|
Abstract
Body
Background. Bone marrow mesenchymal stem cells (BM-MSCs) are widely used in oncology, due to their ability to influence on inflammation, cell survival and migration. But effect of BM-MSCs on tumor cells is contradictory. MSCs can stimulate and inhibit the tumor process, depending on the components of the microenvironment, genesis and stage of differentiation. The aim of this study was to characterize the influence of biologically active substances from human bone marrow mesenchymal stem cells (hBM-MSCs) on proliferation, survival, receptor profile of MCF-7 in vitro and to analyze effect of mouse bone marrow mesenchymal stem cells (mBM-MSCs) on development of Ehrlich` carcinoma in vivo.
Methods. MCF-7 cell line (breast adenocarcinoma) was chosen as an experimental model in vitro. Laboratory mice Balb/2c, which grafted intramuscularly by EAC cells (Ehrlich`s ascites carcinoma), were chosen as a model in vivo. hBM-MSCs were cultured with multicellular spheroids MCF-7 (3D-culture) by non-contact method. mBM-MSCs were isolated from the thigh bone. Cell suspension (107 cells / ml in PBS) was stored at -200C. The cell cytosol was prepared slow thawing of suspension, and then it was injected to EAC mice every 4 days into the abdominal cavity (106 cells / 1mice). Cell viability was evaluated by MTT assay. Detection of markers was performed using IHC method with primary monoclonal antibodies Cks (clone AE1/AE3, Dako, USA), PanCks 5/6/8/18 (clone 5D3 and LP34, Dako, USA), ER α (clone EP1, Dako, USA), EGFR (Dako, USA), E-cadherin (Dako, USA).
Results. Our results demonstrate that hBM-MSCs have significant cytostatic effect on tumor populations. hBM-MSCs inhibited migration tumor cells to suspention by 50-60% compared with the control. After cocultivation of MCF-7 cells with hBM-MSCs proliferative activity was decreased by 2 times and the ability to migrate in the suspension fraction was reduced by 3.8 times. C-medium from hBM-MSCs reduces the volume of spheroids by 61% compared with the control. The rate of growth of the primary tumor was reduced after the injection of mBM-MSCs cytosol. Disposable injection of mBM-MSC inhibited tumor growth by 13%. Following injection of mBM-MSCs inhibited tumor growth by 31%.